Figure 2: Depicts locomotor activity (indicated by latency to fall from a rotorod as the percent change from baseline performance / 10 min) of mice (n = 6 / group) administered intraperitoneal (i.p.) saline, the kappa opioid receptor agonist, U50,488 (0.3 or 1.0 mg / kg), or the peripherally-restricted kappa opioid receptor agonist, ffir-NH2 (3 nmol, i.c.v. or 1 mg / kg, i.p.). * denotes an interaction wherein the indicated U50,488-administered group significantly differs from the respective saline-administered control group (p < 0.05). ‡ denotes an interaction wherein the indicated ffir-NH2-administered group significantly differs from the respective saline-administered control group (p < 0.05).